Editor’s Choice- Heparin pre-treatment in patients with ST-segment elevation myocardial infarction and the risk of intracoronary thrombus and total vessel occlusion. Insights from the TASTE trial

Abstract

Background:

Pre-treatment with unfractionated heparin is common in ST-segment elevation myocardial infarction (STEMI) protocols, but the effect on intracoronary thrombus burden is unknown. We studied the effect of heparin pre-treatment on intracoronary thrombus burden and Thrombolysis in Myocardial Infarction (TIMI) flow prior to percutaneous coronary intervention in patients with STEMI.

Methods:

The Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia (TASTE) trial angiographically assessed intracoronary thrombus burden and TIMI flow, prior to percutaneous coronary intervention, in patients with STEMI. In this observational sub-study, patients pre-treated with heparin were compared with patients not pre-treated with heparin. Primary end points were a visible intracoronary thrombus and total vessel occlusion prior to percutaneous coronary intervention. Secondary end points were in-hospital bleeding, in-hospital stroke and 30-day all-cause mortality.

Results:

Heparin pre-treatment was administered in 2898 out of 7144 patients (41.0%). Patients pre-treated with heparin less often presented with an intracoronary thrombus (61.3% vs. 66.0%, p<0.001) and total vessel occlusion (62.9% vs. 71.6%, p<0.001). After adjustments, heparin pre-treatment was independently associated with a reduced risk of intracoronary thrombus (odds ratio (OR) 0.73, 95% confidence interval (CI)=0.65–0.83) and total vessel occlusion (OR 0.64, 95% CI=0.56–0.73), prior to percutaneous coronary intervention. There were no significant differences in secondary end points of in-hospital bleeding (OR 0.84, 95% CI=0.55–1.27), in-hospital stroke (OR 1.17, 95% CI=0.48–2.82) or 30-day all-cause mortality (hazard ratio 0.88, 95% CI=0.60–1.30).

Conclusions:

Heparin pre-treatment was independently associated with a lower risk of intracoronary thrombus and total vessel occlusion before percutaneous coronary intervention in patients with STEMI, without evident safety concerns, in this large multi-centre observational study.

Keywords

Heparin pre-treatment STEMI

Get full access to this article

View all access options for this article.

References

Davies

Thomas

. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984; 310: 1137–1140.

Badimon

Chesebro

Badimon

. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation 1992; 86: III74–III85.

Libby

. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013; 368: 2004–2013.

Sianos

Papafaklis

Daemen

et al . Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: The importance of thrombus burden. J Am Coll Cardiol 2007; 50: 573–583.

Singh

Berger

Ting

et al . Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience). Am J Cardiol 2001; 88: 1091–1096.

White

Ramee

Collins

et al . Coronary thrombi increase PTCA risk. Angioscopy as a clinical tool. Circulation 1996; 93: 253–258.

Stone

Cox

Garcia

et al . Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: Analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104: 636–641.

Rakowski

Dudek

Dziewierz

et al . Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: The HORIZONS-AMI trial. EuroIntervention 2013; 8: 1307–1314.

Zeymer

Huber

et al . Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: Results from the ASSENT-4 PCI study. Eur Heart J Acute Cardiovasc Care 2012; 1: 136–142.

10.

Brodie

Webb

Cox

et al . Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). Am J Cardiol 2007; 99: 1680–1686.

11.

Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg

James

SK, et al

. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619.

12.

O’Gara

Kushner

Ascheim

et al . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2013; 82: E1–E27.

13.

Garcia

Baglin

Weitz

et al . Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e24S–e43S.

14.

Verheugt

Liem

Zijlstra

et al . High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: Results of the Heparin in Early Patency (HEAP) pilot study. J Am Coll Cardiol 1998; 31: 289–293.

15.

Zijlstra

Ernst

de Boer

et al . Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction. J Am Coll Cardiol 2002; 39: 1733–1737.

16.

Chung

Han

Cho

et al . Effects of the early administration of heparin in patients with ST-elevation myocardial infarction treated by primary angioplasty. Circ J 2007; 71: 862–867.

17.

Ariza

Ferreiro

Sanchez-Salado

et al . Early anticoagulation may improve preprocedural patency of the infarct-related artery in primary percutaneous coronary intervention. Rev Esp Cardiol (Engl Ed) 2013; 66: 148–150.

18.

Giralt

Carrillo

Rodriguez-Leor

et al . Time-dependent effects of unfractionated heparin in patients with ST-elevation myocardial infarction transferred for primary angioplasty. Int J Cardiol 2015; 198: 70–74.

19.

Dangas

Caixeta

Mehran

et al . Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 2011; 123: 1745–1756.

20.

Liem

Zijlstra

Ottervanger

et al . High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: The Heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol 2000; 35: 600–604.

21.

Frobert

Lagerqvist

Gudnason

et al . Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationale. Am Heart J 2010; 160: 1042–1048.

22.

Frobert

Lagerqvist

Olivecrona

et al . Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2013; 369: 1587–1597.

23.

Jernberg

Attebring

Hambraeus

et al . The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart 2010; 96: 1617–1621.

24.

Gibson

de Lemos

Murphy

et al . Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: A TIMI 14 substudy. Circulation 2001; 103: 2550–2554.

25.

Sianos

Papafaklis

Serruys

. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol 2010; 22: 6B–14B.

26.

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985; 312: 932–936.

27.

Steg

van ’t Hof

Hamm

et al . Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369: 2207–2217.

28.

Shahzad

Kemp

Mars

et al . Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): An open-label, single centre, randomised controlled trial. Lancet 2014; 384: 1849–1858.

29.

Mehilli

Kastrati

Schulz

et al . Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: A randomized double-blind trial. Circulation 2009; 119: 1933–1940.

30.

Van’t Hof

Ten Berg

Heestermans

et al . Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomised controlled trial. Lancet 2008; 372: 537–546.

31.

Ellis

Tendera

de Belder

et al . Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358: 2205–2217.

32.

Montalescot

Zeymer

Silvain

et al . Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: The international randomised open-label ATOLL trial. Lancet 2011; 378: 693–703.

33.

Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): Randomised trial. Lancet 2006; 367: 569–578.

34.

Dangas

Mehran

Nikolsky

et al . Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: The HORIZONS-SWITCH analysis. J Am Coll Cardiol 2011; 57: 2309–2316.

35.

Silvain

Beygui

Barthelemy

et al . Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: Systematic review and meta-analysis. BMJ 2012; 344: e553.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.18 MB